Werewolf Therapeutics (HOWL) vs RenovoRx (RNXT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
RenovoRx (RNXT) has outperformed Werewolf Therapeutics (HOWL) over the past year, gaining 18.3% versus a gain of 8.4%. Over five years, RNXT leads with a -85.3% price change compared with -93.7% for HOWL. Werewolf Therapeutics is the larger company by market cap ($46.0 million vs $45.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HOWL | RNXT |
|---|---|---|
| Share price | $0.9466 | $0.942 |
| Market cap | $46.00M | $45.45M |
| 1-day change | -3.97% | -10.29% |
| YTD return | +49.31% | +12.14% |
| 1-year return | +8.43% | +18.34% |
| 5-year return | -93.68% | -85.26% |
| EPS (TTM) | $-0.58 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.12M |
| Revenue growth (YoY) | — | +2511.63% |
| Net income (latest FY) | $-60.82M | $-11.17M |
| Gross margin | — | 70.88% |
| Operating margin | — | -1113.98% |
| Net margin | — | -994.48% |
| 52-week high | $1.20 | $2.59 |
| 52-week low | $0.27 | $0.77 |
| Distance from 52-week high | -21.12% | -63.63% |
| Analyst consensus | none | none |
| Avg. price target upside | +639.49% | +656.90% |
| Average volume | 1.08M | 815.75K |
| Shares outstanding | 48.60M | 48.25M |
| Employees | 39 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
HOWL vs RNXT FAQ
Which is bigger, Werewolf Therapeutics or RenovoRx?
Werewolf Therapeutics (HOWL) is larger, with a market capitalization of $46.00M compared with $45.45M for RenovoRx (RNXT).
Which stock has performed better over the past year, HOWL or RNXT?
RNXT returned +18.34% over the past 12 months, compared with +8.43% for HOWL (price return, excluding dividends). Past performance does not predict future results.
Are Werewolf Therapeutics and RenovoRx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.